Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 155,000 shares, a growth of 105.0% from the January 15th total of 75,600 shares. Based on an average daily volume of 185,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 29.1% of the shares of the stock are short sold.

Bone Biologics Trading Up 1.0 %

NASDAQ BBLG opened at $1.04 on Friday. The company’s 50 day simple moving average is $1.05 and its 200 day simple moving average is $1.40. Bone Biologics has a 12 month low of $0.80 and a 12 month high of $4.49.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.